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Summary 
The barrier function of blood vessels is thought to be regulated at least in part by endothelium. 
This concept is supported  by the dramatic loss of barrier function occurring in the hyperacute 
rejection of vascularized grafts mediated by anti-endothelial ceU (EC) antibodies and complement. 
In this process, the endothelium is not destroyed but instead loses the ability to retain blood 
cells and plasma proteins within capillaries. The noncytotoxic mechanism that allows this change 
in EC function has been unknown. Here we report that within 10 to 20 rain of exposure to 
human xenoreactive natural antibodies and complement, porcine EC undergo alterations in cell 
shape and in the cytoskeleton that disrupt monolayer integrity and lead to formation of intercellular 
gaps. Gap formation is not associated with cell death but requires the complement complex 
C5b67. The gaps induced by anti-EC antibodies and complement are transient; gap closure requires 
formation of C5b-9 complexes on the ceils and the rate of recovery depends on the release of 
cellular products into the medium. Preincubation of EC with dibutyryl cAMP (0.5 raM) prevents 
gap formation and disruption of the cytoskeleton caused by antibodies and complement. These 
results provide evidence that the integrity of endothelium is regulated by components of the 
complement system and suggest a mechanism that may explain the prominent loss of endothelial 
integrity seen in humoral immune responses. 
V 
ascular endothelium plays a pivotal role in regulating 
the movement of macromolecules,  solutes, and blood 
cells (1) across blood vessel walls into tissues. This "barrier 
function" of endothelium is subject to dynamic regulation 
by various mechanisms. For instance, vascular permeability 
is increased by the action on endothelium of such inflamma- 
tory mediators  as histamine,  bradykinin, thrombin, IL-loe 
and TNF-oe (1-6), whereas vascular permeability is decreased 
by heparan sulfate, cyclic AMP (cAMP) 1, phosphodiesterase 
inhibitors, prostaglandins, atrial natriuretic peptide, catechola- 
mines, and ~32-adrenoreceptor stimulators such as isoproter- 
enol and terbutaline  (7-11). 
The boundary created by endothelium not only confines 
blood cells and macromolecules to the intravascular space, 
it also contributes to the hemostatic balance by separating 
plasma coagulant factors from coagulation activators present 
in the underlying matrix. For instance, interruption of en- 
dothelium exposes tissue factor (elaborated by smooth muscle 
cells [12]) to plasma factor VIIa and yon Willebrand factor 
(synthesized by endothelial cells [EC]; 13) to platelets. The 
tissue factor-VIIa complex activates factor X and/or IX (14), 
1 Abbreviations used in thispaper: cAMP, cyclic AMP; dB-cAMP, dibutyril 
cAMP; EC, endothelial cell; MAC, membrane attack complex; PKC, protein 
kinase C. 
In response to thrombin, platelets become activated (13), ex- 
pressing surface receptors that bind yon Willebrand factor/ 
factor VIII in the subendothelium (15), thus mediating at- 
tachment and aggregation of platelets  (16). 
Perhaps the most dramatic evidence for the physiologic im- 
portance of the barrier function of endothelium is provided 
by hyperacute rejection of vascularized grafts (17-19). Hyper- 
acute rejection, initiated by the binding of xenoreactive anti- 
bodies to donor EC and by the activation of complement, 
is characterized by development of interstitial edema, hemor- 
rhage,  and thrombosis  within minutes of perfusion  of the 
graft by the recipient blood. Whereas the manifestations of 
edema, hemorrhage, and thrombosis  could reflect comple- 
ment-mediated lysis of donor EC, in many cases, the en- 
dothelium remains intact early in the course of rejection and 
thus the pathologic changes reflect a loss of barrier function 
in otherwise potentially viable blood vessels (20, 21). 
The goal of the studies reported here was to elucidate non- 
cytotoxic mechanisms by which anti-EC antibodies and com- 
plement could mediate rapid and profound changes in the 
endothelial barrier.  Reasoning that an abrupt alteration  in 
EC morphology might rapidly compromise the integrity of 
endothelium leading to hemorrhage, edema, and thrombosis, 
we examined the morphology of EC after exposure to xeno- 
reactive natural antibodies  and complement. 
We report that incubation of cultured EC in xenogeneic 
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and complement causes, within minutes, changes in EC mor- 
phology resulting in the formation of intercellular "gaps." 
These changes are noncytotoxic, reversible, and followed by 
an increase in the intracellular level of cAMP. The formation 
of gaps strictly depends on the assembly of C5b-7 complexes 
and can be mediated by homologous as well as heterologous 
complement. Formation of gaps is prevented by cAMP ana- 
logues such as dibutyryl cAMP (dB-CAMP). The restoration 
of endothelial integrity after exposure to anti-EC antibodies 
and complement requires formation of the membrane attack 
complex (MAC) and is hastened by some factor(s)  secreted 
by EC. Our findings thus demonstrate that terminal com- 
plement  complexes  regulate  the  barrier  property  of en- 
dothdium. We postulate that in addition to allowing forma- 
tion of  inflammatory  edema, the gaps may expose preexisting 
inducers of thrombosis in the underlying matrix, such as tissue 
factor and yon Willebrand factor, to plasma coagulation factors 
and platelets, thus explaining the prominent evidence of throm- 
bosis  seen in humoral immune reactions.  Furthermore, by 
allowing mitogens, released from EC or platelets stimulated 
by complement to gain access to vascular smooth musde (22, 
23),  the gaps may contribute to the development of more 
chronic and proliferative  disorders  such as atherosclerosis. 
Materials and Methods 
Materials.  DMEM, t-glutamine, penicillin, and streptomycin 
were purchased from Life Technologies  (Gaithersburg, MD). FCS 
was from Hyclone Laboratories, Inc. (Logan, UT). Human sera 
each immunodepleted of C2, C3, C5,  C6, C7, or C8, purified 
recombinant C5a, C5, C6, C7, and C8, and mouse monoclonal 
anti-human  iC3b antibodies were purchased from Quidel (San 
Diego, CA). NP-40, dB-cAMP, methyl isobutyl xanthine (MIX), 
gelatin (type B, from bovine skin), BSA (fraction V), glutaralde- 
hyde, Limulus amebocyte lysate,  osmium tetroxide,  and alkaline  phos- 
phatase-conjugated  antibodies  were  purchased from Sigma  Chemical 
Co.  (St. Louis, MO).  Forskolin was  supplied by Calbiochem- 
Novabiochem Corp. (La Jolla, CA) Rhodamine-conjugated phal- 
loidin, calcein AM, and ethidium homodimer were obtained from 
Molecular Probes, Inc. (Eugene, OR). Acetylated low density li- 
poprotein (LDL) was obtained from Biomedical  Technologies,  Inc. 
(Stoughton, MA). Monoclonal anti-r~ actin antibodies were pur- 
chased from Accurate  Chemical  & Scientific  Corp. (Westbury,  NY). 
Plastic chamber slides, [3sS]t-methionine  were obtained from ICN 
Biomedicals, Ltd. (Costa Mesa, CA). RIA for cAMP level and 
nCr were from DuPont-NEN  (Wilmington,  DE). 
EC Culture.  Porcine  aortic EC were isolated and cultured as 
previously described (24, 25). EC identity was determined based 
on polygonal  morphology at confluence,  ability  to take up acetyhted 
LDL, and lack of  reactivity with anti-c~  actin antibodies. EC were 
used between passages 5 and 10. The EC monolayers  were grown 
to confluence on gelatin-coated 24-weU, 96-weU plates, glass cov- 
erslips, or plastic chamber slides and were maintained in DMEM 
with 1% FCS for 16-20 h before each experiment. 
Source of Natural Antibodies and Complement.  Well-characterized 
human serum samples were used as a source of xenoreactive nat- 
ural anti-EC antibodies and human complement (26-28). Samples 
of human and porcine blood, collected in sterile and pyrogen-free 
containers, were allowed to dot at 4oC, and the serum fraction 
was then separated and stored in plastic vessels. The Limulus ame- 
bocyte lysate test (29) was used to exclude endotoxin contamina- 
tion in the sera and purified complement components. The titer 
of ~noreactive  natural antibodies in serum was determined by 
ELISA as described previously using the cultured porcine EC as 
a target (24). To obtain xenoreactive natural antibodies, the sera 
were heated to 56~  for 30 rain to inactivate complement. As a 
source of  human complement, samples  of  human serum which were 
immunodepleted of IgM (30) or which contained very low or un- 
detectable levels of xenoreactive  natural antibodies (26) were used. 
These sera are known to have  intact classical  and alternative  pathways. 
Porcine serum was used as a source of homologous complement. 
Assessment of Complement Activation on EC.  After incubation 
with xenoreactive  natural antibodies for 30 min, EC grown in 96- 
well plates were incubated with complement at 37~  for I h and 
fixed with 0.1% glutaraldehyde  containing PBS. Complement ac- 
tivation was determined by measuring deposition of iC3b neoan- 
tigen on ECs by ELISA  using mouse monoclonal  anti-human iC3b 
antibodies fonowed  by alkaline  phosphatase-conjugated goat anti- 
mouse IgG antibodies (24). The amount of complement-depleted 
serum used in different experiments was based on standardization 
of the amount of iC3b generated. Normally, a concentration of 
complement-depleted serum which generates iC3b equal to that 
generated by 10-15% normal serum complement was used. 
Morphology of  Porcine Aortic EC.  Unfixed EC monolayers  were 
examined  by phase contrast microscopy.  For visualization of actin- 
based cytoskeleton,  cultures were fixed  with 3.5% paraformaldehyde 
and 0.1% NP-40 for 15 rain, stained with rhodamine-conjugated 
phalloidin for 45 rain and examined using a Zeiss fluorescence 
microscope. For scanning electron microscopy, EC monolayers 
were fixed in 2.5% ghtaraldehyde for one hour, postf~_ed  in 1% 
osmium tetroxide for 1 h and dehydrated through increasing con- 
centrations of ethanol. Samples were then dried in a Ladd critical 
point-dryer, coated  with gold palladium in a Sputter coater and were 
examined using a Philips scanning electron microscope. 
Quantitation of Gap Formation.  The number of gaps observed 
in the EC monolayer  stained with rhodamine phalloidin, was quan- 
titated with the aid of an ocular grid. In repeated experiments, 
random fields of 100 blocks (0.4 mm  2) were examined. In an in- 
dividual  block, an area where two EC had lost contact was counted 
as one gap. Each test condition shown here is representative  of  mul- 
tiple experiments; the values depict the mean of three quantita- 
tions from a single experiment. 
Viability of CulturedEC.  The viability  of  EC exposed to x~nore- 
active natural antibodies and complement was evaluated  using cal- 
cein AM (31), ethidium homodimer (32), nCr release (25), [3sS]- 
methionine incorporation, and staining with 0.4%  trypan blue. 
For staining with calcein AM and ethidium homodimer, EC 
after exposure to xenoreactive  natural antibodies and complement, 
were washed with PBS to remove  residual serum. They were then 
covered with a solution containing 2.0 ~M calcein AM and 4.0 gM 
ethidium homodimer and incubated at 37~  for 30 min. The cells 
were rinsed with fresh solution, mounted, and evaluated  by fluores- 
cence microscopy. 
Cytotoxicity of antibodies and complement was measured by 
51Cr release. EC were labeled with SlCr (2/~Ci/well)  for 3 h at 
37~  washed and incubated with DMEM containing antibodies 
and complement. The percent nCr release was a measure of cy- 
totoxicity of human serum on porcine EC and was determined as 
described (25). 
The metabolic activity of EC was also measured by incorpora- 
tion of [3sS]methionine. After exposure to antibodies and comple- 
ment for 1 h, EC were washed and incubated in [3SS]methionine 
(100/zCi/ml) for 4 h. At that time the EC were washed and ex- 
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and incorporation of 3ss was determined in a liquid scintillation 
counter. 
Measurement oft.AMP Levels.  The intracellular level of cAMP 
was measured  by ILIA  (9). In preparation for cAMP measurement, 
EC were grown to confluence  in 24-weU plates and incubated with 
DMEM containing 25% xenoreactive  natural antibodies and com- 
phment. After treatment with natural antibodies and complement, 
EC were washed with PBS containing 1 mM MIX to inhibit phos- 
phodiesterase and to prevent subsequent breakdown of cAMP. EC 
monolayers were lysed by addition of 5% ice-cold TCA at 4~ 
for a period of 1 h. The TCA-sohble supernatant was removed 
and extracted three times with 5 ml of ethyl ether saturated with 
H20,  then dried and resuspended in 400 ml of sodium acetate 
buffer (pH 6.2). Samples were added to the tracer [mI]CAMP and 
cAMP antiserum complex. The mixture was incubated at 4"C for 
18 h, spun at 1,500g for 15 rain at 4~  decanted, and the radioac- 
tivity of the pellets was determined using a gamma scintillation 
counter. 
Results 
Binding of  Xenoreactive  Natural Antibodies to Porcine  EC and 
Activation of Complement.  Fig. 1 A  shows binding to cul- 
tured EC of xenoreactive IgM present in two sera. The serum 
containing xenoreactive IgM is depicted by Ab +  and the 
serum free of xenoreactive natural antibodies is represented 
by Ab-  and is used as the source of complement. After the 
exposure of EC to various concentrations of Ab +, there was 
a linear relationship between binding of xenoreactive IgM 
antibodies and the concentration of serum up to 30% (Fig. 
1 A). Activation of complement measured by the amount 
of iC3b deposited on EC was a linear function of IgM binding 
up to 25% and complement concentrations up to 10% (Fig. 
1, B and C). 
Morphologic Changes Induced by Xenoreactive Natural Anti- 
bodies and Complement.  Within 10-30 rain after exposure 
to 25% xenoreactive natural antibodies and complement, a 
significant portion  of EC  lost  polygonal appearance  and 
cell-cell contact appeared to be disrupted (Fig. 2 B). Altera- 
tion in morphology required both natural antibodies and ac- 
tivation of  complement since neither complement alone (serum 
￿9  with low or undetectable amount of xenoreactive natural an- 
tibodies) nor antibodies (inactivated serum) induced morpho- 
logical changes (Fig.  2,  C  and D).  Consistent with these 
results, exposure of EC to x~noreactive natural antibodies fol- 
lowed by C2- or C3-depleted serum did not cause morpho- 
logical changes (not shown). 
The morphologic change in EC monolayers in response 
to xmaoreactive  natural antibodies and complement was studied 
by scanning electron microscopy (Fig. 2, E  and F). Treated 
monolayers had holes or openings between individual cells 
and the EC appeared  to protrude from the plate as if they 
had contracted. 
Exposure of the cultured EC to a xenogeneic serum under 
the conditions mediating morphological change did not cause 
cell lysis. Our observations indicate that xenoreactive natural 
antibodies and complement, at the concentrations used in 
our studies, had no detectable cytotoxic effect on porcine aortic 
EC. EC exposed to natural antibodies and complement: (a) 
took up calcein AM; (b) excluded ethidium homodimer-1 
as did controls (Fig. 3, C and D); (c) excluded trypan blue; 
and (d) did not release SlCr (Fig. 3 E). Furthermore, the cells 
remained metabolically active as they incorporated the same 
amount of [3SS]methionine during the 4 h of incubation as 
the controls. These results are consistent with our prior ob- 
servation, as well as others, that cultured EC are relatively 
resistant to lysis (25). 
Although morphological changes in response  to stimuli 
such as endotoxin have been described (33), it is unlikely that 
"contaminants" led to the formation of gaps reported here. 
First, the sera used as the source of natural antibodies and/or 
complement were  always  collected under conditions that 
would limit contamination by environmental agents. Second, 
incubation of EC with sera lacking natural antibodies or com- 
ponents of complement did not cause alteration in cell shape 
as described below. Third, gap formation mediated by anti- 
bodies and complement was seen within minutes whereas 
endotoxin-induced EC shape changes are only noticeable at 
24 h  (33). 
Examination of Actin-based Cytoskeleton.  The disruption 
of the integrity of the EC monolayer has been associated with 
alterations in the actin-based cytoskeleton (34).  To evaluate 
if such changes occurred in response  to binding of natural 
antibodies and activation of complement, the microfilament- 
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Figure  1.  Binding  of human natural antibodies  to 
porcine aortic  EC and activation  of complement.  The 
titer of natural antibodies  in human  serum was deter- 
mined by F.LISA  using the cultured porcine EC as a 
target (24). (A) Titration  of  xenoreactive  natural IgM 
antibodies in human sexual Ab § is the source of nat- 
ural antibodies for B and C, and Ab-  is a serum 
deficient in xenoreactive  natural IgM antibodies and 
is the source of complement for B and C. Activation 
of complement on EC was me~ared by dq)ofition 
of iC3b neoantigen as described in Materials and 
Methods. (B) Deposition of iC3b on EC precoated 
with various concentratiom  of human natural anti- 
bodies and inoabated with 25% of human comple- 
ment. (C) Deposition  of iC3b on EC prer  with 
25% human natural antibodies and incubated with 
various concentrations  of human complement. 
23  Saadi and Hatt Figure  2.  Interruption ofEC monolayers 
by natural antibodies and complement. The 
morphology of monolayers  of porcine EC 
treated with human natural antibodies and 
complement for a period of 30 min was ex- 
amined by phase contrast microscopy (A-D) 
and scanning electron microscopy (E and F). 
(A) EC monolayer treated with 20% natural 
antibodies and complement has intercellular 
gaps (arrows).  (B) EC monolayer treated with 
20% natural antibodies remains  intact. (C) 
EC monolayer treated with 20% human com- 
plement remains intact. (D) EC monolayer 
treated with medium remains intact. (E) EC 
monolayer incubated in tissue culture medium 
reveals no discontinuities by scanning  elec- 
tron microscopy. (F) EC monohyer incubated 
with 10% natural antibodies and complement 
shows large gaps by scanning electron micros- 
copy. (Arrows)  Disrupted areas,  xlO0 (A-D) 
and  x 1000 (E and F). 
based cytoskeleton was  visualized by staining with rhoda- 
mine phalloidin which specifically binds to F-actin (Fig. 4). 
In untreated monolayers, postconfluent EC were spread out; 
the microfilament bundles at the periphery of cells appeared 
as one dense band shared by adjacent cells and their central 
microfilament  bundles (stress fibers) were short and randomly 
located (Fig. 4 A). Within a few minutes of treating the EC 
with natural antibodies and complement, peripheral bands 
of some cells became more distinct from their neighbors and 
thdr central microtilament  bundles condensed, shortened, and 
appeared to fuse (Fig. 4 B). The EC appeared  to have con- 
tracted and become smaller resulting in the formation of in- 
tercellular gaps and interruption of monolayer. Whereas nei- 
ther natural antibodies nor complement alone induced gap 
formation in EC, EC monolayers treated with natural anti- 
bodies did reveal actin polymerization manifested by promi- 
nent peripheral bands and elongated central stress fibers in 
the absence of cell contraction and gap formation (Fig.  4, 
C  and D).  In addition to the formation of gaps,  exposure 
of the endothelial monolayer to xenoreactive natural antibodies 
caused some EC to become detached from plates creating an 
occasional "window" in the monolayer. 
The association  between the formation of gaps in EC 
monolayers and the activation of complement was not re- 
stricted to the heterologous systems used in most experiments. 
As Fig. 5 shows, porcine EC exposed to human xenoreactive 
natural antibodies and then to porcine serum as a source of 
complement, developed gaps that were morphologically in- 
distinguishable from those mediated by human complement. 
Although the number of gaps caused by porcine complement 
was less than the number caused by human complement, the 
results demonstrate that interruption of monolayer can be 
mediated by homologous complement components. 
To evaluate changes in morphology, the number of gaps 
per 0.4 mm  2 in EC monolayer was determined in experi- 
ments where the concentration of natural antibodies and com- 
plement were varied independently. The number of gaps was 
a linear function of antibody concentration between 2.5 and 
25% of levels in serum (Fig. 6 A). After exposure to natural 
antibodies,  the number of gaps was a function of comple- 
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Figure  3.  Viability  of EC treated with nat- 
ural antibodies and complement. The viability 
of porcine EC exposed to human natural anti- 
bodies and complement was evaluated using cal- 
cein  AM,  ethidium homodimer (A-D)  and 
slCr release (E) as described in Materials  and 
Methods. (A) EC monolayer treated with 75% 
human serum. (B) EC monolayer treated with 
medium. (C) EC monolayer treated with 25% 
human serum for 30 rain, antibodies, and com- 
plement was replaced by fresh  tissue culture 
medium and cells were stained 210 min later. 
(D) EC monolayer treated with 25% human 
serum for 30 min.  (E) Cytotoxicity of 25% 
human natural antibodies and complement as- 
sessed by release of slCr at 30  and 60 min. 
24  Perturbation of Endothelial Integrity Induced by Complement Figure 4.  Gap formation in monolayers of 
porcine EC induced by human natural anti- 
bodies and complement.  Porcine EC mono- 
layers were treated for 30 min with human nat- 
ural antibodies  and complement,  fixed, and 
stained with rbodamine*conjugated phalloidin 
as described  in Materials  and Methods. Gap for- 
marion was induced only in monolayers treated 
with antibodies plus complement or antibodies 
plus C8-depleted serum. (.4) EC monolayer  un- 
treated. (B) EC monoleyer treated with 25% 
natural antibodies and complement.  (C) EC 
monolayer  treated with 25% natural antibodies. 
(D) EC monolayer treated with 25% comple- 
ment. (E) EC monolayer treated with 25% nat- 
ural antibodies  and complement depleted  of  C8. 
(F) EC monolayer treated with 25% natural 
antibodies and complement  depleted of C5. 
Arrows denote gaps. x400. 
ment concentration (Fig. 6 B). It should be pointed out that 
because we defined a gap as an area where EC have lost con- 
tact, larger gaps, possibly resulting  from the fusion of two 
or three smaller gaps, were counted as one. This factor prob- 
ably limited the increase in the numbers of gaps seen with 
higher  concentrations  of complement  (Fig.  6 A).  The size 
of gaps appeared to be larger at higher concentrations of com- 
plement whereas the actual number of gaps did not increase. 
Kinetic Analysis of Gap Formation in EC Monolayers in Re- 
stmnse to NaturaI  Antibodies  and Complement.  The time course 
for alteration in EC morphology after exposure to xenoreac- 
tive natural  antibodies  and complement is depicted in Fig. 
7. Gaps were present as early as 10 min and the maximum 
number  of gaps was seen by 30 min  after treatment. 
Role of  Complement Components in Mediating Change in EC 
Morphology.  To gain  insight  into  the role of complement 
components  in  mediating  gap formation,  pooled sera  im- 
munodepleted of individual complement components were 
used as the source of complement.  In repeated experiments, 
sera depleted of C8 mediated gap formation in monolayers 
of EC pretreated with  antiendothelial  antibodies (Fig.  4 E 
and Fig. 8), indicating that neither C8 nor C9 is needed for 
the formation of gaps.  In contrast, serum depleted of C5 did 
not  cause gap formation  (Fig.  4 F  and  Fig.  8).  The func- 
tional  activity of C5-depleted serum  was restored by addi- 
tion of purified C5. Therefore, the complement component 
which  stimulates  gap formation  is  derived from  C5. 
The role of CSa in  gap induction  was examined by ex- 
posing EC monolayers to either recombinant C5a, in the pres- 
ence and absence of natural antibodies,  or CSa generated by 
the addition of cobra venom factor to whole serum (Fig.  8). 
Gap formation  was not induced in  either case,  suggesting 
C5b, the initiator of terminal complement complex forma- 
tion  has  a major  role in  this  event. 
The requirement for C5b was substantiated by the inability 
of sera depleted of C6  or C7  to cause EC contraction.  In 
both cases, gap formation was restored by addition of purified 
C6 or C7, respectively. Thus, gap formation in EC monolayers 
Figure 5.  Gap formation in monolayers  of  porcine EC induced by human 
natural antibodies and porcine complement.  Monolayers of porcine EC 
were incubated for 30 min with 25% heat-inactivated human serum as 
source of EC antibodies and then with 25% porcine serum as a source 
of homologous complement.  The cells were then fixed and stained as de- 
scribed  in Materials and Methods. Gaps were observed  in monolayers  treated 
with human anti-porcine EC antibodies plus porcine complement  but not 
in controls treated with porcine serum alone. (A) EC monolayer treated 
with human natural antibodies plus porcine complement. (B) EC monohyer 
treated with porcine serum alone. Arrows denote gaps. x400. 
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Figure 6.  Dose-response  for gap formation induced by natural anti- 
bodies and complement.  Monolayers of porcine aortic EC treated with 
human natural antibodies and complement were fixed, stained, and quan- 
titated as described in Materials and Methods. (.4) EC were incubated with 
various concentrations of natural antibodies for 30 rain after which they 
were e~posed to 25% complement for 30 min. (B) EC were incubated 
with 25% natural antibodies for 30 min after which they were exposed 
to various concentrations of complement.  The values depict the mean of 
three quantitations for a single experiment. 2 
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Figure  7.  Kinetics  of gap formation 
induced by natural antibodies and com- 
plement. Monolayers  of porcine aortic EC 
pretreated with 25% human natural an- 
tibodies for 30 min were exposed to 25% 
complement  for various periods of time 
at 37~  Gaps were quantitated as de- 
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Figure  8.  Role  of complement  components  in  formation  of  gaps. 
Monolayers of porcine aortic EC precoated with 25% human natural anti- 
bodies were treated with serum depleted of C5, C6, C7, or C8 and then 
fixed. Gaps in monolayers were counted as in Fig. 6. Only natural anti- 
bodies  and  complement  (Ab+C) and  serum  depleted  of  C8  (20%, 
Ab+AC8)  induced gap formation.  Gaps were not formed in monolayers 
exposed to natural antibodies and serum depleted of C5 (25%, Ab+AC5), 
C6 (30%, Ab+AC6), or C7 (30%, Ab+AC7). Neither recombinant CSa 
(75 #g/m1,  in absence or presence of antibodies) nor CSa generated by 
CVF (4 U/ml) caused gap formation.  Sera depleted of C5, C6, or C7 
were reconstituted  with 150 #g/ml of purified C5, C6, or C7,  serum 
depleted of C8 with 30 #g/ml of C8, and are indicated by +C5,  +C6, 
+C7, and  +C8. 
is induced by C5b-7.  Addition of purified C8 to C5b-7 al- 
most doubled the number of gaps (in one representative ex- 
periment it increased from 23 to 47) suggesting that C8 aug- 
ments the effect  of C5b-7. 
Recovery of  EC Monolayers  after Disruption  by Natural  Anti- 
bodies and Complement.  Two lines of evidence indicate that 
the formation of gaps in monolayers of EC mediated by nat- 
ural antibodies  and complement is a transient phenomenon. 
First, in repeated experiments,  scrutiny of a single disrupted 
area, visible by phase contrast  microscopy over a period of 
5 h revealed that the integrity of the monolayer was restored 
(not shown). Second, analysis of morphology at various times 
after exposure to natural antibodies and complement showed 
that the gaps disappeared within 6 h (Fig.  9 E). In all cases, 
concurrent with the closure of gaps, cells spread out and be- 
came morphologically indistinguishable from cells that had 
never been exposed to xenoreactive  natural antibodies  and 
complement. 
The events leading to gap closure appear to require addi- 
tional complement components that are not involved in gap 
induction. This was suggested by the observation  that after 
exposure of EC to natural antibodies and CS-depleted serum, 
gaps did not spontaneously dose (Fig.  9 F).  Progressively, 
these cells  developed  larger gaps and many of the calls ap- 
peared rounded and completely detached from their neighbors. 
Addition of purified C8 or forskolin  (see below) to the C8- 
depleted  serum restored gap closure.  These results  suggest 
that MAC and cAMP may have a role in restoration  of the 
integrity of the EC monolayer. 
In repeated experiments,  the closure of EC gaps in mono- 
layers after treatment  with xenoreactive  natural antibodies 
and complement was delayed when the treatment  medium 
containing antibodies  and complement  was replaced after 
60 min by fresh culture medium. Ultimately, the endothelial 
gaps closed after removal of the treatment medium and replace- 
ment with fresh culture medium. However, 2 h after exposure 
to antibodies  and complement, the number of gaps was far 
higher in these monolayers than in monolayers remaining in 
the original treatment  medium (Fig.  10). This observation 
suggests that the recovery of monolayers might require some 
factor(s) released from the EC. 
Figm'r  9.  Cellular mechanism regulating 
gap formation and restoration of integrity of 
porcine EC monolaym. Porcine EC mono- 
layers treated with fonkolin, MIX, or dB- 
c.Al~ for I h or untr~ted were then ~0o~ed 
to 25% whole human serum for 30 min and 
stained for l~-actin. Formation of gaps medi- 
ated by natural antibodies and complement 
was  inhibited  by forskolin,  MIX,  or  riB- 
(A-D). (A) Untrea~ EC monohy,r. 
(B) EC monohyer treated with 10/~M for- 
skolin. (C) EC monohyer treated with 100 
/~M MIX. (D) EC monohyer treated with 
1/~M dB-c.AMP. Restoration of EC mono- 
layer integrity in 6 h required MAC (E and 
F). (E) EC monohyer treated with whole 
serum. (F) EC monolayer treated  with serum 
depleted of C8. Arrows denote gaps. x400. 
26  Perturbation of Endothelial  Integrity  Induced by Complement Prevention of Gap Formation by cAMP Analogues.  Eleva- 
tion of intracellular concentration of cAMP enhances the per- 
meability barrier (9). To determine if CAMP protects the EC 
monolayer against xenoreactive natural antibodies and com- 
plement, we tested the effect of reagents that increase the 
intracellttlar concentration of  cAMP. As shown in Fig. 9, prein- 
cubation of EC in 2 mM dB-cAMP inhibited gap formation 
in response to xenoreactive natural antibodies and comple- 
ment when examined 30 min after  the treatment (Fig. 9). 
Concurrent with the appearance of distinct peripheral bands 
and stress fibers, EC became flatter and assumed their polyg- 
onal shape. As little as 0.5 mM dB-cAMP inhibited gap for- 
mation (Fig.  11 A).  In contrast, 2 mM dB-cGMP did not 
inhibit gap formation induced by xenoreactive natural anti- 
bodies and complement (Fig. 11 B). The effect of dB-cAMP 
was mimicked  by the adenylate cyclase activator forskolin and 
by the cyclic nucleotide phosphodiesterase inhibitor MIX. 
Forskolin and MIX, at concentrations of 10 #M and 100 #M 
respectively, protected EC against natural antibodies and com- 
plement. Increased intracdlular levels of cAMP induced by 
forskolin or MIX caused EC to spread out, to have more or- 
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Figure  11.  Effect  of CAMP on gap formation induced by natural anti- 
bodies and complement. Monolayers  of  pordne aortic EC exposed to cAMP 
and cGMP analogues for 30 min were then treated with 25~  antibodies 
and complement.  Gaps were quantitated as described in Fig. 6. Gap for- 
mation induced by antibodies and complement was inhibited by CAMP 
analogues but not by cGMP analogues. (A) The number of gaps in EC 
monolayers treated with various concentrations of dB-cAMP. (B) Number 
of gaps in EC monolayers treated  with dB-cAMP (2 mM), dB-cGMP 
(2 mM), forskolin (10/~M),  and MIX (100/~M). 
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Figure 10.  Role of treatment medium in resto- 
ration of integrity of porcine EC monolayers. EC 
monolayers were treated with 25% natural anti- 
bodies and complement for  1 h,  the treatment 
medium was then replaced by fresh tissue culture 
medium, and incubation was continued for  1 h 
at 370C. Gaps in monolayers were counted as de- 
scribed  in Fig. 6. Substitution of treatment medium 
containing  natural antibodies and complement  by 
fresh tissue culture medium delayed gap closure. 
(A) Numbers of gaps in EC monolayers either 
maintained  in treatment medium containing nat- 
ural antibodies and complement (Control) or the 
treatment medium was replaced  by fresh tissue cul- 
ture medium (DMEM). (/3) EC monolayer treated 
as control in A. (C) EC monolayer incubated in 
DMEM, as in A.  x400. 
eral bands (Fig.  9). Forskolin induced some changes in the 
cytoskeleton represented by ruffled peripheral bands. 
The Effect of Xenoreactive Natural Antibodies and Comple- 
ment on cAMP Level.  Since devation of intracellular cAMP 
by forskolin and cAMP analogues  inhibited gap formation 
mediated  by natural antibodies and complement, we inquired 
whether the intracellular level of cAMP was reduced by ex- 
posure to xenoreactive  natural antibodies and complement. 
In fact, we found an increase in intracellular levels of CAMP 
in response to natural antibodies and complement (Fig. 12). 
Such a rise was both transient and more profound in cells 
treated with CS-depleted serum (C5b-7) than in ceils treated 
with whole serum (C5b-9).  The devation in the intracel- 
lular level of CAMP was detected as early as 15 rain and dis- 
appeared by 60 rain. The results  suggested that formation 
of MAC prevented accumulation of CAMP, perhaps due to 
leakage from the cells. 
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Figure  12.  Induction  of cAMP synthesis in EC by antibodies and com- 
plement. EC precoated with 25% antibodies were treated with 25% serum 
complement (C5b-9) or 25% serum depleted of C8 (C5b.7) for various 
periods of time. Total cAMP level was measured by RIA as described in 
Materials and Methods. Values depict the mean of four measurements for 
a single experiment. and were used after confluence, we observed variations in the 
number of gaps, the kinetics of gap formation, and the recovery 
time with cells from different animals. This can be explained 
by variations in the number of binding sites for xenoreactive 
natural antibodies and the source of natural xenoreactive an- 
tibodies, which varied in some experiments. However, when 
the same ceils and the same source of antibodies were used, 
the experimental results were highly reproducible. 
Discuss/on 
The barrier function of endothelium which controls the 
movement of macromolecules  and cells from circulating blood 
to the surrounding tissues is compromised in many patho- 
logic states. Perhaps the most dramatic alteration in barrier 
function is seen  in hyperacute rejection of vascularized organs 
mediated by anti-EC antibodies and complement where in- 
terstitial  hemorrhage,  edema and  thrombosis  develop in 
minutes to hours (17-19). Our results suggest that the aber- 
rant function of endothelium in hyperacute rejection and per- 
haps in other conditions mediated by humoral immunity may 
be due, in part to alteration in the structure of EC leading 
to the formation of intercellular gaps. The formation of gaps 
is a noncytotoxic event associated  with alteration in the actin- 
based cytoskeleton and with an increase in the level of cAMP. 
Our results show that the formation of gaps can be induced 
by C5b67 complexes although it is amplified by the full com- 
plement cascade. The endothelial gaps induced by antibodies 
and complement are transient, restoration of endothelial in- 
tegrity resulting from alterations induced by MAC and per- 
haps by some factor(s) released by EC. 
The system used in our experiments involved exposure of 
EC to a heterologous serum as a model for the reaction that 
might occur in a xenogeneic organ graft.  In homologous 
systems, complement activation is controlled at the level of 
C3/C5 convertase by decay-accelerating factor (35, 36) and 
membrane cofactor protein (37) and at the level of MAC for- 
mation by CD59 (38). That these molecules may function 
less effectively  against heterologous than against homologous 
complement could in part explain the enhanced susceptibility 
of a xenograft to complement-mediated  injury (39, 40). Al- 
though altercation in EC shape might be expected to be more 
severe  in a heterologous system such as a vascularized  xenograft, 
our experiments reveal that these changes also occur when 
EC are the target of homologous complement (Fig. 5). In 
light of this finding, it would seem appropriate to consider 
whether some changes in models such as Forsmann  shock 
and the Arthus reaction might result in part from the direct 
action of complement on endothelium. 
Modulation of barrier formation by natural antibodies and 
complement is not a consequence of cell lysis and does not 
require insertion of MAC. Although transmembrane channels 
formed by MAC can normally lyse erythrocytes,  nucleated 
cells seem to be more resistant to complement-mediated killing 
and more effective molecules of complement are required to 
lyse nucleated cells than erythrocytes (41). We showed that 
the concentrations  of natural antibodies  and complement 
which induced gap formation were not cytolytic to EC (Fig. 
2); therefore, the holes in the monolayer were neither by- 
products of lysis nor removal of EC. Furthermore, MAC or 
even C5b-8 needed for cytolysis was not required for inter- 
ruption of the monolayer since depletion of C8 still induced 
gaps. 
Modulation of barrier function by natural antibodies and 
complement is reversible. The existence of  gaps in monolayers 
was transient and disappearance seemed to depend on forma- 
tion of MAC. The latter was supported by the persistence 
of gaps in cell monolayers treated with C8-depleted  serum 
(Fig. 9 F).  Restoration of the integrity of EC monolayers 
may also require release of some factor(s) from endothelium, 
possibly stimulated through MAC.  This was suggested by 
the observation that when the medium containing natural 
antibodies and complement was replaced by fresh medium 
that did not contain natural antibodies and complement, there 
was a delay in repair of monolayers (Fig. 10). 
Disruption of EC monolayers by natural antibodies and 
complement was abrogated by cAMP. In systems where the 
endothelial  barrier function is impaired by mediators of  inflam- 
mation, barrier function can be restored by agents that in- 
crease the intracellular concentration of cAMP (8, 9, 42, 43). 
The exact role of CAMP in the restoration of  barrier function 
of endothelium in these systems is still obscure; however, ele- 
vation of intracellular CAMP relaxes EC cytoskeleton and in- 
creases cell-cell contact (44). We showed that the gap forma- 
tion in EC mediated by the action of natural antibodies and 
complement was eliminated by an increase in intracellular 
concentration of cAMP caused by dB-CAMP, forskolin, or 
MIX (Figs. 9 and 11). This suggests that activation of a cAMP- 
dependent system protects the barrier function in our system 
as well. 
Clearly, natural antibodies and complement delivered  signals 
to the cultured EC as indicated by the increase in intracel- 
lular level  of cAMP (Fig. 12). However, a significantly higher 
level of cAMP was observed when serum depleted of C8 was 
used (Fig. 12 B). Given what is known about signaling by 
complement C5b-7 and C5b-9 complexes (for a review see 
reference 45), it is unlikely that C5b-7 is a more potent in- 
ducer of the cAMP synthesis. Rather, we think that cAMP 
is lost  from EC treated  with C5b-9;  that loss may occur 
through membrane channels  just as shown in Ehrlich cells (46). 
One  possible  mechanism  underlying  the  recovery  of 
monolayers of endothelium treated with natural antibodies 
and complement may involve the synthesis of cAMP (Fig. 
12) since we showed that cAMP abrogated gap formation 
(Fig. 9 D). When adenylate cyclase  activity was inhibited by 
GDP-b-S which inhibits the G-protein, EC treated with nat- 
ural antibodies and complement never recovered (not shown). 
Clearly the level of intracellular cAMP is not the only factor 
since gaps do not close in cells treated with C5b-7 that have 
increased intraceUular cAMP level. 
Antibodies and complement could elicit protein kinase C 
(PKC) activation  and increase in the intracellular  level of 
Ca  2+ as in other systems (46). Such signaling by natural an- 
tibodies and complement may account for recovery of EC 
from humoral injury and changes in cytoskeleton as discussed 
below. Restoration  of EC monolayers may be linked to or 
28  Perturbation  of Endothelial Integrity Induced by Complement be a consequence of elimination of MAC, a process which 
requires C5-9 (47) and is mediated by increase in Ca  2  § and 
PKC activation (48). In systems where C8 is depleted, PKC 
is not activated (46) and the C5b-7 complex is eliminated 
more slowly than C5b-9 (47). In our experiments, depletion 
of C8 from serum prevented recovery (Fig. 9 F), suggesting 
a possible relationship between recovery and elimination of 
the complex. 
Activation of PKC and an increase in the intracellular level 
of Ca  2+ in EC induced by natural  antibodies and comple- 
ment may lead to rearrangement of actin cytoskeleton by the 
following mechanism. Upon phosphorylation by PKC, the 
actin binding protein MARCKS, which anchors actin struc- 
tures to plasma membrane, loses its affinity for actin. In the 
presence  of  high  levels of  Ca  2+,  MARCKS  binds  to 
calmodulin.  Thus binding to actin is inhibited,  resulting in 
changes in the actin cytoskeleton (49, 50). Activation of PKC 
and an increase in the intracellular level of Ca  2  + have been 
linked to morphological changes in EC mediated by thrombin 
(51,  52). 
The barrier function of endothelium is regulated by var- 
ious mechanisms. The movement of solutes, fluid, and cells 
from blood to tissues because of disruption of endothelium 
mediated by the action of inflammatory mediators, ultimately 
can be hindered by activation of ~-adrenergic receptors, and 
by the action of some prostaglandins  and cAMP (1, 2, 53, 
54). Our data suggest that the formation of  gaps in monolayers 
of  EC induced by antibodies and complement is another con- 
dition where disruption of endothelium is transient and can 
be restored, perhaps by mechanisms that require newly syn- 
thesized cellular products. Our findings further support the 
notion that the exchange between blood and tissues is sub- 
ject to dynamic regulation in order to maintain the balance 
of macromolecules and cells in the vasculature. 
Whereas we have shown that generation of C5b67 is es- 
sential for the formation of gaps, it may not be sufficient. 
The formation of gaps may depend upon other factors in 
serum. This concept is supported by preliminary studies sug- 
gesting that gap formation could not be induced in serum- 
free conditions  and by our prior studies on the release of 
heparan sulfate from cultured EC (27). 
The transient increase  in pe,iieability of  endothelium medi- 
ated by natural antibodies  and complement in the absence 
of cytolysis  could play a major role in the pathology of hyper- 
acute rejection by promoting edema, thrombosis, and extrava- 
sation of macromolecules and blood cells. Whereas we have 
focused on hyperacute rejection as a model,  the changes in 
cell shape and endothelial integrity discussed here may con- 
tribute to a variety of tissue lesions. For example, loss of bar- 
rier function of endothelium might also contribute to the 
development of atherosclerosis, where injury to endothelium 
(55) and complement activation play a role (56,  57). 
We have shown that heparan sulfate is released from EC 
in response to antibody binding and complement activation 
(25). EC release basic fibroblast growth factor and platelet- 
derived  growth factor in response  to MAC (22, 23). The poten- 
tial interaction of these growth factors with soluble heparan 
sulfate has been shown to modulate their mitogenic activity 
(58) and such effects might be anticipated in the system we 
studied.  Further, interruption of endothelium induced by 
C5b-7 or MAC may allow leakage into extravascular species 
of these mitogenic factors leading to proliferation of vascular 
smooth muscle cells (22) and thus to the development of  more 
chronic changes such as atherosderosis. 
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